Lane Clark & Peacock LLP

ID-500

Retrospective study on real-world IBD care using Discover data: analyzes patient characteristics, treatment patterns (e.g., 5-ASA, budesonide), co-medication impact, and outcomes to inform guidelines and optimize personalized management.

Inflammatory bowel disease (IBD), which includes conditions like ulcerative colitis and Crohn’s disease, result in longterm illnesses that can cause painful symptoms, affect daily life, and often require ongoing treatment. By using Discover, we aim to better understand how these conditions are currently being treated in real-world settings. We will look at which medicines are being prescribed, how they are used over time, and how well they work for different groups of patients. This includes treatments like budesonide and 5-ASAs, which are commonly used to help control inflammation and maintain remission. We’ll also explore how other medicines, such as acid-reducing drugs, might affect how well these treatments work. This is important because some combinations of medicines may reduce effectiveness or increase the risk of flare-ups, even when patients follow their treatment plans correctly. By identifying patterns in prescribing and outcomes, we can highlight what is working well and where improvements are needed. This means doctors will have better information to guide their decisions, helping them choose the most suitable treatments for each patient. It could also lead to updates in clinical guidelines and support more personalised care. This for patients may mean fewer relapses, better symptom control, and improved quality of life. It may also help reduce unnecessary treatments and avoid side effects from medicines that are not working as intended. Overall, the project aims to make IBD care safer, more effective, and more tailored to individual patients.

05/01/2026

01/08/2026

18/12/2025

De-Personalised

22/12/2025

TRE